Methodological advances~Cardiac MR
Amongst the various brain disorders known today it is undoubtedly stroke that has experienced the largest impact of in-vivo MR methods. In clinical stroke management today, MR based imaging tools are used routinely, due to their sensitivity and versatility, for early and differential diagnosis. The actual cause of a stroke, i.e. the stenosis or occlusion of a cerebral artery, can be visualized by MR angiography and the resulting reduction of cerebral blood flow quantified by perfusion weighted imaging (PWI). Diffusion weighted imaging (DWI) detects changes in water diffusion that occur very early in the ischemic brain as a consequence of the rapid increase in intracellular water. Brain edema, i.e. increased tissue water content occurring later but preceding necrosis and apoptosis, as well as early and late hemorrhages (e.g. subarachnoid, respectively hemorrhagic transformation), are exquisitely detectable by TI and T2 weighted MRI. Supplementary to imaging, spectroscopic MR methods (MRI) are increasingly used in clinical stroke diagnosis, allowing to quantify at an early time point markers of the metabolic derangements typical for stroke, such as pH, Pi, PCr, ATP, lactate and later hallmarks of neurodegeneration, such as Nacetylaspartate. MR based methods will play a crucial role in clinical stroke management also in the future, as they are expected to contribute significantly to solving currently existing problems with stroke treatments. Such areas of concern are: (1) Tissue staging: stroke patients that will optimally benefit from neuroprotecrive treatments need to be identified, based on differential diagnosis and staging of brain tissue that is salvageable and irreversibly damaged. This is essential for the success of any neuroprotective treatment that inevitably also carries some risk; (2) Proof-of-concept: in phase III clinical stroke trials most drugs so far failed to show the efficacy expected based on animal models. It is therefore getting increasingly difficult to justify initiation of large stroke trials before having proven in a small cohort that at least some effects observed in the experimental animal models are also seen in man. MR methods are extensively used in animals as well and being a valuable link therefore offer themselves as a unique opportunity to solve this problem; (3) Relation of morphology to function: up to now, the development in animal models of effective therapies for acute stroke presumed that reducing the infarct size will also promote functional improvement. However, both in animals and humans functional recovery occurs late after stroke onset, i.e. independent from any change in lesion size. Functional MRI, in combination with morphological MRI and MRS, does and will enable us to gain more detailed insight into this relationship that certainly is fundamental to any clinically successful therapeutic approach in stroke.
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Scope: Since the origin of MRI, very spectacular improvements and new applications have occured which strongly relied on emerging technologies, such as powerful computer hardware, large-bore high-homogeneity magnet design, extremely fast and accurate field-gradient control, implementation of digital RF transceivers .... Today the technical domain from which most significant advances could occur probably is RF coil development, with trends in high-frequency resonators, phased arrays with increasing numbers of coils, miniature RF probes for surface or endoscopic observation and efficiency boosting by cryogenic means. Sensitivity limits are assigned either with large coils at very high field or with small coils at lower fields. In order to clarify the topic, we focus here on the question of the RF detection efficiency as a function of both the NMR frequency and the volume of interest. Underlying Physics: The sensitivity of the RF detection in MRI can be defined (using the reciprocity principle) bl/ the factor 2~ v o B1/x/P, where v o is the NMR frequency and B 1 the amplitude of the excitation field produced by the RF coil supplied with a power P. In usual clinical applications P is almost entirely absorbed in tissues inside the volume of interest and increases as v o for a given B I. Thus the RF sensitivity is almost independent of v 0, the SNR gain with increasing field being due to the increased nuclear magnetization. However at small volumes of interest or at low NMR frequencies the RF absorption in tissues may become negligible as compared to the power dissipation in the coil windings, leading to a degradation of the RF efficiency. The latter also degrades with large coils at high NMR frequencies mainly due to radiation problems and to RF penetration effects inside the body which strongly depend on the conductivity and of the permittivity of the tissues.
Determinant Technical Factors:
Classical RF coils have been based on the distribution of capacitive and inductive lumped elements. New designs using transmission-line or cavity resonators now allow to implement efficient NMR probes well beyond the standard lower and upper size and frequency limits. The design of high-frequency resonators have been of great help to implement MRI applications over large volumes above 2 Tesla. Using high-temperature superconducting material and NMRcompatible cryogenic set-up, improvements have also been reported for applications at low field or more recently for localized microscopy at the surface of the body at 1.5 T.
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High field MR from head to toe applications Ewald Moser. NMR Group. Institute/or Medical Physics, University of Vienna, Vienna. Austria Recent developments in nuclear magnetic resonance hardware (see also the previous speaker) and methodology enable MRI and MRS at ultrahigh magnetic fields. Theoretical improvements depend on model assumptions and organ size and suggest a linear increase in signal-to-noise ration (SNR) at least. In practice however, certain experiments may be limited by several factors including hardware performance, technical and physiologic artifacts, etc. After a short introduction, high field MR applications --from head to toe, shall be presented. This will include human in vivo MR spectroscopy (single voxel and 2D/3D-spectroscopic imaging) of brain QH), skeletal muscle and liver (13C/3JP). high resolution MRI and MRA of human extremities, and MR-angiography, MR-venography. Perfusion and BOLD-fMRI of the human brain at 3 Tesla. Additional examples may also include 7 T data on extremities. Actual advantages of high field MR may include increased spectral resolution, SNR, CNR, spatial and/or temporal resolution, sensitivity, specificity and/or reduced overall measurements time, however, this may be gained only via an optimized protocol and only for certain parts of the human body. Ischemic heart disease comprises the following clinical entities: Stable angina, unstable angina, acute myocardial infarction, chronic left ventricular dysfunction post-myocardial infarction (remodeling). Although each of these clinical situations carries specific diagnostic requirements, in principal, complete characterization of the patient with ischemic heart disease necessitates measurement of global left and right ventricular function, regional wall motion, regional perfusion, coronary artery anatomy, coronary flow and cardiac metabolism. Established diagnostic methods all have major limitations: EKG demonstrates electrical consequences of ischemia, but sensitivity, specificity and spatial resolution are limited. Echocardiography ( + stress) allows analysis of wall motion and possibly of perfusion, but is often limited by poor image quality. Nuclear scintigraphy is limited to analysis of function and perfusion, and requires use of radioactive tracers. Positron emission tomography offers measurement of perfusion and metabolism, but is expensive, has Iimited availability and again requires radioactive tracers. Catheterbased angiography allows high-resolution analysis of coronary anatomy and of ventricular function, but is invasive, does not measure perfusion or coronary flow, and requires X-ray exposure. On the other hand, MRI, at least in principle, offers analysis of all relevant parameters, carries no patient risk and does not use radiation. Intrinsically 3D MRI is the accepted gold standard for measurement of myocardial mass and volumes. Regional wall motion can be studied at rest and during stress, and for detection of stress-induced wall motion abnormality in coronary disease, MRI is superior to echocardiograpby. MR tagging and tissue phase mapping may further refine analysis of regional wall motion. MR allows analysis of myocardial perfusion with high temporal resolution based on first pass of MR contrast agents and, possibly in the future, also without use of contrast using spin labelling techniques. Although now technically feasible, the superiority of first pass-MR perfusion measurements over other methods (nuclear or echo) still needs to be demonstrated in larger clinical studies. MR coronary angiography is feasible, although the spatial resolution has been limited to ~ 1 ram. Navigators. intravascular contrast agents and newer pulse sequences (e.g. FLASH/EPI hybrids) may bring resolution towards 500 pro. Because of intrinsic patient movement, resolution beyond this will necessitate real time coronary imaging, and it is presently unclear whether the technical requirements for this can be developed. Even without the ability to provide highest-resolution coronary images, MRI may allow exclusion of coronary disease or evaluation of stenosis severity by measurement of coronary flow velocities using phase velocity imaging. Finally, in principle, MR spectroscopy allows to detect the regional consequences of stress-induced ischemia or of sear formation (loss of phosphocreatine, accumulation of inorganic phosphate), but sensitivity of this method currently limits voxes sizes to ~ 20 cm 3. .Vlajor technical advances are needed
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